Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

amrecibart

An anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, amrecibart targets and binds to the apple 2 (A2) domain of FXI and activated FXI (FXIa), thereby preventing the intrinsic pathway-triggered FXI activation. This prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-factor XI antibody REGN9933
anti-factor XI monoclonal antibody REGN9933
anti-FXI monoclonal antibody REGN9933
Code name:REGN 9933
REGN-9933
REGN9933
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search